Health Condition 1: H348- Other retinal vascular occlusions
Conditions
Interventions
Intervention1: SMPL- subthreshold micropulse laser 577 nm combined with intravitreal Ranibizumab injection (0.5mg/0.05 ml) in group A: Patients in group A will be additionally treated with SMPL 577nm
Sponsors
Aravind eye hospital chennai
Eligibility
Inclusion criteria
Inclusion criteria: patient with treatment naive branch retinal vein occlusion with macular edema with central macular thickness more than 275 micrometres measured using HRA spectral domain for optical coherence tomography with BCVA equal to or less than 6/9
Exclusion criteria
Exclusion criteria: 1. any other retinal vascular pathology for example diabetic retinopathy 2. co-existent ocular pathology 3. history of cataract surgery in the previous 3 months 4. history of vitreoretinal surgery 5. history of pan retinal photocoagulation in the last 6 months 6. history of previous grid laser treatment 7. history of intravitreal injections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SMPL in combination with anti-VEGF therapy may have equivalent/ non-inferior efficacy (CMT reduction, visual acuity improvement) than anti-VEGF monotherapyTimepoint: At 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| SMPL combination with anti-VEGF therapy likely to reduce the number of anti- VEGF injectionTimepoint: At 4 months | — |
Countries
India
Contacts
Public ContactDr Kanan Agrawal
Outcome results
None listed